These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 28511260)

  • 1. Botulinum Toxin Therapy for Parkinson's Disease.
    Wagle Shukla A; Malaty IA
    Semin Neurol; 2017 Apr; 37(2):193-204. PubMed ID: 28511260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-oriented approach to botulinum toxin use.
    Jankovic J
    Toxicon; 2009 Oct; 54(5):614-23. PubMed ID: 19073203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the use of botulinum toxin therapy in Parkinson's disease.
    Mills R; Bahroo L; Pagan F
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):511. PubMed ID: 25407133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin in the management of parkinsonian disorders.
    Grippe T; Chen R
    Toxicon; 2023 Aug; 232():107209. PubMed ID: 37429465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
    Sheffield JK; Jankovic J
    Expert Rev Neurother; 2007 Jun; 7(6):637-47. PubMed ID: 17563247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of botulinum toxin in Parkinson's disease.
    Jocson A; Lew M
    Parkinsonism Relat Disord; 2019 Feb; 59():57-64. PubMed ID: 30579818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal.
    Jost WH
    Toxins (Basel); 2021 Jan; 13(2):. PubMed ID: 33503872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease.
    Jost WH
    J Neural Transm (Vienna); 2016 Jan; 123(1):51-5. PubMed ID: 26138438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum Toxin Therapy for Nonmotor Aspects of Parkinson's Disease.
    Sławek J; Madaliński M
    Int Rev Neurobiol; 2017; 134():1111-1142. PubMed ID: 28805566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
    Marion MH; Humberstone M; Grunewald R; Wimalaratna S
    Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
    Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
    Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Digestive disorders in Parkinson's disease: dysphagia and sialorrhea].
    González-Fernández J; Prieto-Albin R; Velasco-Palacios L; Jorge-Roldán S; Cubo-Delgado E
    Rev Neurol; 2010 Feb; 50 Suppl 2():S51-4. PubMed ID: 20205142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
    Santamato A; Panza F; Solfrizzi V; Frisardi V; Ranieri M; Fiore P
    J Rehabil Med; 2008 Nov; 40(10):882-3. PubMed ID: 19242630
    [No Abstract]   [Full Text] [Related]  

  • 14. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
    Ondo WG; Hunter C; Moore W
    Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    J Neurol; 2009 Apr; 256(4):563-7. PubMed ID: 19401804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin treatment in parkinsonism.
    Anandan C; Jankovic J
    J Neurol Sci; 2024 Jan; 456():122810. PubMed ID: 38056063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to onset and duration of botulinum toxin efficacy in movement disorders.
    Ledda C; Artusi CA; Tribolo A; Rinaldi D; Imbalzano G; Lopiano L; Zibetti M
    J Neurol; 2022 Jul; 269(7):3706-3712. PubMed ID: 35113259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins.
    Narayanaswami P; Geisbush T; Tarulli A; Raynor E; Gautam S; Tarsy D; Gronseth G
    Parkinsonism Relat Disord; 2016 Sep; 30():73-7. PubMed ID: 27406786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin treatment of secretory disorders.
    Naumann M; Jost W
    Mov Disord; 2004 Mar; 19 Suppl 8():S137-41. PubMed ID: 15027066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.